| Association between the 1291-C/G polymorphism in the adrenergic α-2a receptor and the metabolic syndrome. | |
| | |
MedLine Citation:
|
PMID: 21105277 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
The prevalence of the metabolic syndrome is increased in patients with schizophrenia compared with the general population. The strong interindividual differences in susceptibility to developing the metabolic syndrome suggests that the genetic makeup is a modulating factor. Part of the genetic puzzle can possibly be explained by variations in the gene coding for the adrenergic α-2a receptor (ADRA2A) because this receptor plays an important role in lipolysis. Three studies have found an association between the α-2a 1291-C/G polymorphism and antipsychotic induced weight gain, with conflicting results between whites and Asians. No studies have been published investigating the association between the 1291-C/G polymorphism and the metabolic syndrome. The primary objective of this cross-sectional study was to investigate the association between the ADRA2A 1291-C/G polymorphism and the metabolic syndrome in 470 patients using antipsychotic drugs. There was no significant association between carriership of the variant 1291-G allele and prevalence of the metabolic syndrome (odds ratio, 0.73; 95% confidence interval, 0.49-1.15). Exploratory analysis showed an association between carriership of the variant 1291-G allele and a reduced prevalence of the metabolic syndrome in patients not currently using antipsychotics (odds ratio, 0.05; 95% confidence interval, 0.003-0.97; P = 0.048). In conclusion, this study shows that the ADRA2A 1291-C/G polymorphism does not seem to be a strong predictor for long-term occurrence of the metabolic syndrome in antipsychotic using patients. Studies investigating this association using a prospective, or retrospective, design, as well as studies investigating this association in a nonpsychiatric population, are warranted. |
| | |
Authors:
|
Arne J Risselada; Jelle Vehof; Richard Bruggeman; Bob Wilffert; Dan Cohen; Asmar F Al Hadithy; Johan Arends; Hans Mulder |
Related Documents
:
|
18159097 - Apolipoprotein a5 ivs3+476a allelic variant associates with increased trigliceride leve... 19834957 - Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential... 16522997 - The metabolic syndrome and its relationship to hypertensive target organ damage. 14742767 - The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin. 8018047 - Choreoathetosis/ballismus associated with pentamidine-induced hypoglycemia in a patient... 19632427 - Facial flushing due to multifocal tumorlets in the lung with bronchiectasis. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of clinical psychopharmacology Volume: 30 ISSN: 1533-712X ISO Abbreviation: J Clin Psychopharmacol Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-23 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8109496 Medline TA: J Clin Psychopharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 667-71 Citation Subset: IM |
Affiliation:
|
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treat...
Next Document: Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxi...